Cetera Investment Advisers
KYMR icon

Cetera Investment Advisers’s Kymera Therapeutics KYMR Stock Holding History

Cetera Investment Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,602
Closed -$300K – 5100
2026
Q1 		$300K Buy
3,602
+252
+8% +$20K ﹤0.01% 3984
2025
Q4 		$261K Buy
+3,350
New +$226K ﹤0.01% 4027

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Cetera Investment Advisers's KYMR Position: Q2 2026 in Review

Cetera Investment Advisers sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 3,602 shares — an estimated $300K sold.

Cetera Investment Advisers first reported a position in KYMR in Q4 2025 and held it in 2 quarters. The position peaked at $300K in Q1 2026. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Cetera Investment Advisers reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 3,602 Kymera Therapeutics shares in Q2 2026, an estimated $300K.
  • Cetera Investment Advisers first reported a position in Kymera Therapeutics in Q4 2025 and held it in 2 quarters.
  • Cetera Investment Advisers's Kymera Therapeutics position peaked at $300K in Q1 2026.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.